France· FR:68932534
SYNAGIS 50 mg/0,5 ml, solution injectable
A medicinal product containing palivizumab, registered in France by ASTRAZENECA AB.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PALIVIZUMAB
- Manufacturer
- ASTRAZENECA AB
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009300723181 flacon(s) en verre de 0,5 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palivizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandSynagisAstraZeneca AB
- United StatesSynagisSwedish Orphan Biovitrum AB (publ)
- IrelandSynagis 50 mg/0.5 ml and 100 mg/1 ml Solution for injectionAstraZeneca AB
- NetherlandsSynagis 100 mg/ml, oplossing voor injectieAstraZeneca AB
- BelgiumSynagis 100 mgAstraZeneca
- United KingdomSynagis 100mg powder and solvent for solution for injection vialsAbbVie Ltd
- NorwaySynagisAstraZeneca
- SpainSYNAGIS 100 mg POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEAstrazeneca Ab
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Synagis
- Liechtenstein · Synagis
- Norway · Synagis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/def279b4-db81-4337-8515-99dde6cd0d83 GET /v1/drugs/def279b4-db81-4337-8515-99dde6cd0d83?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68932534",
"date_amm": "2014-08-22",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/99/117",
"substance": "PALIVIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "intramusculaire",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about palivizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.